Vanguard Portfolio Management’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.33M Sell
755,589
-519,832
-41% -$6.02M ﹤0.01% 2265
2026
Q2
$14.9M Buy
1,275,421
+20,585
+2% +$294K ﹤0.01% 2073
2026
Q1
$21.1M Buy
+1,254,836
New +$22.5M ﹤0.01% 1881

Other funds holding CLB

Vanguard Portfolio Management's CLB Position: Q3 2026 in Review

Vanguard Portfolio Management reduced its Core Laboratories (CLB) stake by 41% in Q3 2026, selling an estimated $6.02M and leaving 755,589 shares worth $7.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Vanguard Portfolio Management first reported a position in CLB in Q1 2026 and has held it in 3 quarters since. The position peaked at $21.1M in Q1 2026. 180 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • Vanguard Portfolio Management held 755,589 shares of Core Laboratories worth $7.33M as of Q3 2026.
  • Vanguard Portfolio Management sold 519,832 Core Laboratories shares in Q3 2026, an estimated $6.02M.
  • Core Laboratories made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #2265 holding.
  • Vanguard Portfolio Management first reported a position in Core Laboratories in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Portfolio Management's Core Laboratories position peaked at $21.1M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.